Inclusion Criteria:

          -  Histologically confirmed recurrent or persistent squamous cell carcinoma,
             adenosquamous carcinoma, or adenocarcinoma of the cervix after progression on or after
             1-2 lines of prior systemic chemotherapy in the metastatic/recurrent setting that is
             not amenable to curative treatment with systemic chemotherapy, surgery, and/or
             radiotherapy

          -  Radiologically-measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1

          -  Cervical cancer tissue for study analysis (archival or fresh biopsy specimen)

          -  Life expectancy of at least 12 weeks

          -  Adequate hematologic and organ function

          -  Female of childbearing potential must be willing to comply with adequate contraception

        Exclusion Criteria:

          -  Treatment with investigational therapy with therapeutic intent within 28 days prior to
             randomization

          -  Active or untreated central nervous system (CNS) or brain metastases

          -  Active or history of autoimmune disease or immune deficiency

          -  Active tuberculosis

          -  Known, clinically significant liver disease

          -  Severe infection per investigator judgement at the time of randomization or any active
             infection that, in the opinion of the investigator, could impact patient safety

          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,
             anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies

          -  Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination
             half-lives (whichever is longer) prior to randomization

          -  Treatment with systemic immunosuppressive medications within 1 week prior to
             randomization or anticipation of need for systemic immunosuppressive medication during
             study

          -  Pregnant or breastfeeding woman

          -  Known hypersensitivity to any component of the tiragolumab or atezolizumab
             formulations